Revelation Biosciences REVB 深 滬
等待開盤 09-25 09:30:00 美东时间
0.8702
-0.064
-6.87%
華盛通- 最 高0.9377
- 今 開0.92
- 成交量 7.09万股
- 最 低 0.8599
- 昨 收 0.9344
- 總市值 346.64万
- 52周最高 6.76
- 市盈率 靜 --
- 換手率 1.78%
- 52周最低 0.8599
- 委 比 -93.55%
- 總股本 398.34万
- 歷史最高 2276064.00
- 量 比 2.35
- 振 幅 8.33%
- 歷史最低 0.8599
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Revelation Biosciences Grants Performance-Based Executive Stock Awards
An announcement from Revelation Biosciences ( ($REVB) ) is now available. On Au...
08-20 05:29
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
– Study on track to begin later this year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service cont...
08-19 21:05
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses of $(7.01) per share from the same period last year.
08-07 05:18
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more than 10% of all hospitalized patients and more than 50% of patients admitted to int...
08-03 21:03
Revelation Biosciences Adopts Stockholder Rights Protection Plan
An update from Revelation Biosciences ( ($REVB) ) is now available. On July 10,...
07-14 05:12
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that its Board of Directors (the "Board") has adopted a stockholder rights plan (the "Rights Plan") a...
07-11 04:07
Revelation Biosciences Updates Executive Contracts, Shareholder Actions
Revelation Biosciences ( ($REVB) ) has shared an update. On June 24, 2026, Reve...
06-25 05:19
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
05-09 00:05
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
05-08 04:56
